Mucosolvan® is a pharmacy-only drug containing the active ingredient ambroxol hydrochloride, which is used for mucolytic action in acute and chronic lung diseases and diseases of the lower respiratory tract where there is a disorder of mucus formation and mucus transport.


If hypersensitivity (allergy) to one of the ingredients of the medication is known or occurs, the medication must not be used any further, as this may result in dangerous health damage. Likewise, the use of Mucosolvan® is not recommended if there is a disturbed self-cleaning of the lower respiratory tract and large amounts of secretion. In this case, a congestion of secretions could otherwise occur. If kidney function is impaired or there is a serious liver disease, Mucosolvan® should only be used with external caution (i.e. at greater intervals or in reduced doses).

Instructions for use

Unless the doctor prescribes a different dose, Mucosolvan is taken as a film-coated tablet in children 12 years of age and older and adults as follows During the first 2-3 days, 1⁄2 tablet is taken 3 times a day (30mg Ambroxol hydrochloride 3 times a day). Afterwards 2 times a day 1⁄2 tablet (thus 2 times 30mg Ambroxolhydrochlorid) is taken. It is possible to increase the effect in adults by taking a whole tablet twice a day (i.e. 60 mg ambroxol hydrochloride twice a day).

This can be particularly helpful in cases of markedly increased secretion production in the lower respiratory tract or viscous respiratory secretion. The duration of use must be determined individually by the doctor. The medication should be taken after meals unchewed with a glass of water, juice or tea.

Side effects

As with all medicines, there may be adverse effects when taking this medicine. These include the following:

  • Gastrointestinal disorders such as nausea and abdominal pain
  • Hypersensitivity reactions (reddening of skin and mucous membranes)
  • Facial Swelling
  • Shortness of breath
  • Temperature rise
  • Chills
  • Dryness of the mouth and respiratory tract
  • Increased salivation
  • Nose Running
  • Constipation
  • Complaints during urination

Related Articles:

Amlodipine (Norvasc)

Products Amlodipine is commercially available in tablet form (Norvasc, generic). It has been approved in many countries since 1990. Amlodipine is also combined fixed with the following agents: Aliskiren, atorvastatin, perindopril, telmisartan, valsartan, olmesartan, hydrochlorothiazide, and indapamide. Structure and properties Amlodipine (C20H25ClN2O5, Mr = 408.9 g/mol) has a chiral center

Read More »

Effervescent Powder

Products Some pharmaceuticals, medical devices and food products are commercially available as effervescent powders. However, effervescent tablets or granules are much more commonly used today. Effervescent powders should be stored away from moisture. Structure and properties Effervescent powders are powders that usually contain an acid such as citric acid or

Read More »


Products Phenylpropanolamine is no longer on the market as a human drug in many countries. It was formerly contained in Astho-Med Syrup, Contac, Dimetane, Dimetapp, and Slim Caps, among others. Structure and properties Phenylpropanolamine (C9H13NO, Mr = 151.21 g/mol) has a phenylethylamine structure and exists as a racemate. The salt

Read More »

Boiling Point

Definition and properties The boiling point is the characteristic temperature at which a substance passes from the liquid to the gaseous state. The liquid and gaseous phases are in equilibrium at this point. A typical example is water, which starts boiling at 100 °C and becomes water vapor. The boiling

Read More »

Inhalation Anesthetics

Products Inhalation anesthetics are commercially available as volatile liquids or as gases for inhalation. Structure and properties Most inhalation anesthetics are halogenated ethers or hydrocarbons. Also used are inorganic compounds such as the gaseous nitrous oxide. The halogenated representatives exist as volatile liquids with a different boiling point. Because of

Read More »


Products Idarucizumab is commercially available as an injection/infusion solution (Praxbind). It was approved in the EU and US in 2015 and in many countries in 2016. Structure and properties Idarucizumab is a humanized Fab fragment of an IgG1 monoclonal antibody. It has a molecular weight of approximately 47.8 kDa. Idarucizumab

Read More »
Health Facts